Immediate Reports All 2018 2017 Merchavia Holdings completes successful offering in TASE Merchavia signs MoU for first investment in the medical cannabis sector Merchavia’s portfolio company ‘Juventas’ announces strategic commercialization agreement הוחלט על הרחבת פעילות וכניסה לתחום מו”פ של קנאביס רפואי תשקיע ב-G4P-חב’ בתחום הבריאות הדיגיטלית-סך של 600א’ שח תמורת מניות המהוות 6% ב-G4P Merchavia’s CDx reports positive trial results for early detection of prostate cancer הוצאה לפועל אישרה את מכירת הנכס בנחלה בבת שלמה בכ- 4.1מ’ שח, המשך מ-26.10.17 מכתב מנכ”ל לבעלי המניות-סיכום 6 החודשים הראשונים של 2018 Cardiacsense completed 500K$ investment round on a 20M$ company valuation Positive Results in a Multi-Center Clinical Trial of CDx Juventas’s trial’s end-points for closing wounds on a diabetic foot not met CEO’s letter to shareholders – annual summary Memorandum of Understanding for investing $500,000 in Valens in exchange for allocation of about 6.25% of preferred shares Libental fully repaid loan worth NIS 7 million to Merchavia CDX signs exclusive commercialization agreement with Genomic granting a license to develop and commercialize tests for early diagnosis of prostate cancer CardiacSense completed raising funds from an external investor, after completion the company holds 7.86% Vacation of the property in Beit Shlomo completed, receiver appointed by the company will work for its sale Participation in the investment round of CardiacSense Ltd. Helsinki Committee approves start of trial for CardiacSense’s product Engaging in an investment agreement in CardiacSense All articles loaded No more articles to load
Memorandum of Understanding for investing $500,000 in Valens in exchange for allocation of about 6.25% of preferred shares
CDX signs exclusive commercialization agreement with Genomic granting a license to develop and commercialize tests for early diagnosis of prostate cancer
CardiacSense completed raising funds from an external investor, after completion the company holds 7.86%
Vacation of the property in Beit Shlomo completed, receiver appointed by the company will work for its sale
